Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
Cancer Epidemiol. 2021 Oct;74:101985. doi: 10.1016/j.canep.2021.101985. Epub 2021 Jul 16.
Mutually increased risks for thyroid and breast cancer have been reported, but the contribution of etiologic factors versus increased medical surveillance to these associations is unknown.
Leveraging large-scale US population-based cancer registry data, we used standardized incidence ratios (SIRs) to investigate the reciprocal risks of thyroid and breast cancers among adult females diagnosed with a first primary invasive, non-metastatic breast cancer (N = 652,627) or papillary thyroid cancer (PTC) (N = 92,318) during 2000-2017 who survived ≥1-year.
PTC risk was increased 1.3-fold [N = 1434; SIR = 1.32; 95 % confidence interval (CI) = 1.25-1.39] after breast cancer compared to the general population. PTC risk declined significantly with time since breast cancer (Poisson regression = P <0.001) and was evident only for tumors ≤2 cm in size. The SIRs for PTC were higher after hormone-receptor (HR)+ (versus HR-) and stage II or III (versus stage 0-I) breast tumors. Breast cancer risk was increased 1.2-fold (N = 2038; SIR = 1.21; CI = 1.16-1.26) after PTC and was constant over time since PTC but was only increased for stage 0-II and HR + breast cancers.
Although some of the patterns by latency, stage and size are consistent with heightened surveillance contributing to the breast-thyroid association, we cannot exclude a role of shared etiology or treatment effects.
已有报道称甲状腺癌和乳腺癌的风险相互增加,但这些关联是由病因因素还是增加的医学监测导致的尚不清楚。
利用美国大规模基于人群的癌症登记数据,我们使用标准化发病比(SIR)来调查诊断为第一原发性浸润性、非转移性乳腺癌(N=652627)或甲状腺乳头状癌(PTC)(N=92318)的成年女性中甲状腺和乳腺癌的相互风险,这些女性在 2000-2017 年期间生存时间≥1 年。
与普通人群相比,乳腺癌后 PTC 的风险增加了 1.3 倍(N=1434;SIR=1.32;95%置信区间[CI]为 1.25-1.39)。PTC 风险随乳腺癌后时间显著下降(泊松回归 P<0.001),且仅在肿瘤大小≤2cm 时明显。PTC 后激素受体(HR)+(与 HR-相比)和 II 期或 III 期(与 0 期-I 期相比)乳腺癌的 SIR 更高。PTC 后乳腺癌风险增加了 1.2 倍(N=2038;SIR=1.21;CI=1.16-1.26),且随 PTC 后时间的变化保持不变,但仅在 0 期-II 期和 HR+乳腺癌中增加。
尽管潜伏期、分期和大小的一些模式与增加的监测有助于解释乳腺癌与甲状腺癌的关联,但我们不能排除共同病因或治疗效果的作用。